Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Theodore Phillips

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Neurology. Clinical Practice|May 2, 2013
Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus studyOmar Khan, Aaron E Miller, Carlo Tornatore, et al.
Neurology. Clinical Practice|May 2, 2013
Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus studyCarlo Tornatore, J Theodore Phillips, Omar Khan, et al.
Neurology and Therapy|March 3, 2016
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM StudiesRalf Gold, Gavin Giovannoni, J Theodore Phillips, et al.
Neurology and Therapy|August 4, 2017
Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRMRobert J Fox, Ralf Gold, J Theodore Phillips, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 4, 2014
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS)Ralf Gold, Gavin Giovannoni, J Theodore Phillips, et al.
Clinical Therapeutics|July 29, 2017
Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRMÓscar Fernández, Gavin Giovannoni, Robert J Fox, et al.
European Journal of Neurology|March 23, 2017
Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studiesE Havrdova, G Giovannoni, R Gold, et al.
Journal of Neurology|May 16, 2009
Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacyF Reed Johnson, George Van Houtven, Semra Ozdemir, et al.
Neurology. Clinical Practice|June 28, 2016
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerationsRobert J Fox, Andrew Chan, Ralf Gold, et al.
Neurology and Therapy|February 2, 2019
Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient OutcomesJinny Min, Stanley Cohan, Enrique Alvarez, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Neurology. Clinical Practice|May 2, 2013
Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus studyOmar Khan, Aaron E Miller, Carlo Tornatore, et al.
Neurology. Clinical Practice|May 2, 2013
Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus studyCarlo Tornatore, J Theodore Phillips, Omar Khan, et al.
Neurology and Therapy|March 3, 2016
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM StudiesRalf Gold, Gavin Giovannoni, J Theodore Phillips, et al.
Neurology and Therapy|August 4, 2017
Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRMRobert J Fox, Ralf Gold, J Theodore Phillips, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 4, 2014
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS)Ralf Gold, Gavin Giovannoni, J Theodore Phillips, et al.
Clinical Therapeutics|July 29, 2017
Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRMÓscar Fernández, Gavin Giovannoni, Robert J Fox, et al.
European Journal of Neurology|March 23, 2017
Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studiesE Havrdova, G Giovannoni, R Gold, et al.
Journal of Neurology|May 16, 2009
Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacyF Reed Johnson, George Van Houtven, Semra Ozdemir, et al.
Neurology. Clinical Practice|June 28, 2016
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerationsRobert J Fox, Andrew Chan, Ralf Gold, et al.
Neurology and Therapy|February 2, 2019
Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient OutcomesJinny Min, Stanley Cohan, Enrique Alvarez, et al.
Pageof 5